The Hematology Research Training Program at the University of Pennsylvania was established in 1978 and has provided training for 111 basic, translation and patient-oriented investigators. Since 2004 the program and this T32 have supported 8 postdoctoral and 4 predoctoral trainees per year. The continuing goal of the program is to help individuals interested in the broadly-defined disciplines of hematology prepare for careers as independent investigators. Originally the candidates were drawn almost exclusively from physicians enrolled in the clinical hematology training programs in the Departments of Medicine and Pediatrics. Since 1998 we have included non-physician postdoctoral trainees and since 2004 we have also incorporated predoctoral trainees, with an emphasis on future physician-scientists in Penn's MD-PhD program to take advantage of the Pi's role as the director of that program. The addition of predoctoral MD-PhD and PhD students to the program reflects our belief in the long term value of attracting talented students in hematology-related research at an earlier point in their training as scientists and physician-scientists. Starting in 2006, PhD candidates at Penn, including those in this program, have also had the option of enrolling in the Graduate Training in Medical Sciences (GTMS) Certificate Program, expanding their opportunities for cross training in human biology and disease. Outcomes. During the first 29 years of funding, 103 postdoctoral trainees (66 MD, 13 MD-PhD and 24 PhD) and 8 pre-doctoral trainee (6 MD-PhD and 2 PhD) have been supported. Of the 90 postdoctoral trainees who have completed training, 61% hold full-time appointments at an academic institution and are engaged in either laboratory or clinical research. An additional 9% are engaged primarily in clinical practice, but have university appointments and participate in clinical research projects and teaching part-time. 53% of our former trainees who have completed training have extramural research funding from the NIH and other sources, 11% have positions in industry and 4% are completing further postdoctoral studies. A detailed plan for identifying appropriate predoctoral and postdoctoral candidates, providing them with the skills needed for an independent career, and mentoring them throughout the process is included in the application.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
2T32HL007439-31
Application #
7560460
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Chang, Henry
Project Start
1979-07-01
Project End
2014-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
31
Fiscal Year
2009
Total Cost
$688,679
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brenner, Jacob S; Kiseleva, Raisa Yu; Glassman, Patrick M et al. (2018) The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulm Circ 8:2045893217752329
Bagashev, Asen; Sotillo, Elena; Tang, Chih-Hang Anthony et al. (2018) CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol Cell Biol :
Greineder, Colin F; Villa, Carlos H; Walsh, Landis R et al. (2018) Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting. Bioconjug Chem 29:56-66
Kiseleva, Raisa Yu; Glassman, Patrick M; Greineder, Colin F et al. (2018) Targeting therapeutics to endothelium: are we there yet? Drug Deliv Transl Res 8:883-902
Greineder, Colin F; Johnston, Ian H; Villa, Carlos H et al. (2017) ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model. Blood Adv 1:1452-1465
Thalji, Nabil K; Camire, Rodney M (2017) Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol 24:453-459
George, Lindsey A; Sullivan, Spencer K; Giermasz, Adam et al. (2017) Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med 377:2215-2227
Zhen, Tao; Kwon, Erika M; Zhao, Ling et al. (2017) Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. Blood 130:2431-2442
Peslak, Scott A; Olson, Timothy; Babushok, Daria V (2017) Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol 18:70
Carnemolla, Ronald; Villa, Carlos H; Greineder, Colin F et al. (2017) Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. FASEB J 31:761-770

Showing the most recent 10 out of 118 publications